const data = [
  {
    doc_id: '',
    header: '',
    subheader: '',
    Actual_count: '',
    Total_derive_count: '',
    output: [
      {
        ID: '1',
        actual_text:
          '5.2.1 Inclusion Criteria Subjects may be entered in the study only if they meet all of the following criteria',
        level: '0',
        child: [
          {
            ID: '2',
            actual_text:
              '1. Provided written informed consent prior to enrollment. ',
            level: '1',
            derive_seg: [
              {
                ID: '2.1',
                derive_seg:
                  'Provided written informed consent prior to enrollment.',
              },
            ],
            child: [],
          },
          {
            ID: '3',
            actual_text: '2. Male or female and at least 18 years of age.',
            level: '1',
            derive_seg: [
              {
                ID: '3.1',
                derive_seg: 'Male or female and at least 18 years of age.',
              },
            ],
            child: [],
          },
          {
            ID: '4',
            actual_text: '3. A life expectancy of at least 12 weeks. ',
            level: '1',
            derive_seg: [
              {
                ID: '4.1',
                derive_seg: 'A life expectancy of at least 12 weeks.',
              },
            ],
            child: [],
          },
          {
            ID: '5',
            actual_text:
              '4. Histologically or cytologically confirmed advanced or metastatic solid tumor for which no effective standard therapy is available. ',
            level: '1',
            derive_seg: [
              {
                ID: '5.1',
                derive_seg:
                  'Histologically or cytologically confirmed advanced or metastatic solid tumor for which no effective standard therapy is available.',
              },
            ],
            child: [],
          },
          {
            ID: '6',
            actual_text:
              '5. Patients with recurrent glioblastoma multiforme who satisfy all of the following may be enrolled after discussion between the sponsor and investigator: <TabTab>\uf02d Progressive tumor despite prior treatment with radiation therapy and temozolomide <TabTab>\uf02d Measurable disease by Response Assessment in Neuro-Oncology (RANO) criteria using gadolinium-enhanced MRI scanning <TabTab>\uf02d Either on no glucocorticoids or on a stable dose of dexamethasone not exceeding 4 mg daily for 7 days prior to the first dose of study therapy <TabTab>\uf02d No evidence of intracranial hemorrhage (except for stable grade 1 hemorrhage), not receiving therapeutic anticoagulation or anti-platelet therapy, and has a normal INR and APTT <TabTab>\uf02d No prior treatment with bevacizumab or other antiangiogenic drugs <TabTab>\uf02d No radiation in the past 3 months <TabTab>\uf02d No enzyme-inducing anticonvulsant drugs (eg., phenytoin, carbamazepine) in the 2 weeks prior to the first dose of study therapy ',
            level: '1',
            derive_seg: [
              {
                ID: '6.1',
                derive_seg:
                  'Patients with recurrent glioblastoma multiforme who satisfy all of the following may be enrolled after discussion between the sponsor and investigator',
              },
            ],
            child: [
              {
                ID: '7',
                actual_text:
                  '\uf02d Progressive tumor despite prior treatment with radiation therapy and temozolomide ',
                level: '2',
                derive_seg: [
                  {
                    ID: '7.1',
                    derive_seg:
                      'Progressive tumor despite prior treatment with radiation therapy and temozolomide',
                  },
                ],
                child: [],
              },
              {
                ID: '8',
                actual_text:
                  '\uf02d Measurable disease by Response Assessment in Neuro-Oncology (RANO) criteria using gadolinium-enhanced MRI scanning ',
                level: '2',
                derive_seg: [
                  {
                    ID: '8.1',
                    derive_seg:
                      'Measurable disease by Response Assessment in Neuro-Oncology (RANO) criteria using gadolinium-enhanced MRI scanning',
                  },
                ],
                child: [],
              },
              {
                ID: '9',
                actual_text:
                  '\uf02d Either on no glucocorticoids or on a stable dose of dexamethasone not exceeding 4 mg daily for 7 days prior to the first dose of study therapy ',
                level: '2',
                derive_seg: [
                  {
                    ID: '9.1',
                    derive_seg:
                      'Either on no glucocorticoids or on a stable dose of dexamethasone not exceeding 4 mg daily for 7 days prior to the first dose of study therapy',
                  },
                ],
                child: [],
              },
              {
                ID: '10',
                actual_text:
                  '\uf02d No evidence of intracranial hemorrhage (except for stable grade 1 hemorrhage), not receiving therapeutic anticoagulation or anti-platelet therapy, and has a normal INR and APTT ',
                level: '2',
                derive_seg: [
                  {
                    ID: '10.1',
                    derive_seg:
                      'No evidence of intracranial hemorrhage (except for stable grade 1 hemorrhage), not receiving therapeutic anticoagulation or anti-platelet therapy, and has a normal INR and APTT',
                  },
                ],
                child: [],
              },
              {
                ID: '11',
                actual_text:
                  '\uf02d No prior treatment with bevacizumab or other antiangiogenic drugs ',
                level: '2',
                derive_seg: [
                  {
                    ID: '11.1',
                    derive_seg:
                      'No prior treatment with bevacizumab or other antiangiogenic drugs',
                  },
                ],
                child: [],
              },
              {
                ID: '12',
                actual_text: '\uf02d No radiation in the past 3 months ',
                level: '2',
                derive_seg: [
                  {
                    ID: '12.1',
                    derive_seg: 'No radiation in the past 3 months',
                  },
                ],
                child: [],
              },
              {
                ID: '13',
                actual_text:
                  '\uf02d No enzyme-inducing anticonvulsant drugs (eg., phenytoin, carbamazepine) in the 2 weeks prior to the first dose of study therapy ',
                level: '2',
                derive_seg: [
                  {
                    ID: '13.1',
                    derive_seg:
                      'No enzyme-inducing anticonvulsant drugs (eg., phenytoin, carbamazepine) in the 2 weeks prior to the first dose of study therapy',
                  },
                ],
                child: [],
              },
            ],
          },
          {
            ID: '14',
            actual_text:
              '6. BRCA1 and BRCA2 mutations are not required but enrichment of this patient population is permitted and may be added to completed cohorts considered below the MTD. ',
            level: '1',
            derive_seg: [
              {
                ID: '14.1',
                derive_seg:
                  'BRCA1 and BRCA2 mutations are not required but enrichment of this patient population is permitted and may be added to completed cohorts considered below the MTD.',
              },
            ],
            child: [],
          },
          {
            ID: '15',
            actual_text:
              '7. Small cell lung cancer, high grade serous ovarian cancer, and triple negative breast cancer patients will be preferentially recruited and may be added to completed cohorts considered below the MTD. ',
            level: '1',
            derive_seg: [
              {
                ID: '15.1',
                derive_seg:
                  'Small cell lung cancer, high grade serous ovarian cancer, and triple negative breast cancer patients will be preferentially recruited and may be added to completed cohorts considered below the MTD.',
              },
            ],
            child: [],
          },
          {
            ID: '16',
            actual_text:
              '8. Eastern Cooperative Oncology Group (ECOG) performance status of \u22641. ',
            level: '1',
            derive_seg: [
              {
                ID: '16.1',
                derive_seg:
                  'Eastern Cooperative Oncology Group (ECOG) performance status of \u22641.',
              },
            ],
            child: [],
          },
          {
            ID: '17',
            actual_text: '9. Able to swallow and retain oral medication. ',
            level: '1',
            derive_seg: [
              {
                ID: '17.1',
                derive_seg: 'Able to swallow and retain oral medication.',
              },
            ],
            child: [],
          },
          {
            ID: '18',
            actual_text:
              '10. Adequate bone marrow, liver, and renal function: <TabTab>\uf02d Absolute neutrophil count \u2265 1000/mm 3 <TabTab>\uf02d Platelets \u2265 100,000/mm 3 <TabTab>\uf02d Total bilirubin \u2264 1.5 times the upper limit of normal (ULN) <TabTab>\uf02d Aspartate aminotransferase and alanine aminotransferase \u2264 2.5 x ULN (\u2264 5 x ULN for subjects with known liver metastasis) <TabTab>\uf02d Creatinine clearance \u2265 45 mL/min (calculated by the Cockcroft-Gault formula [see Section 15.0, Appendix 5]). ',
            level: '1',
            derive_seg: [
              {
                ID: '18.1',
                derive_seg: 'Adequate bone marrow, liver, and renal function',
              },
            ],
            child: [
              {
                ID: '19',
                actual_text:
                  '\uf02d Absolute neutrophil count \u2265 1000/mm 3 ',
                level: '2',
                derive_seg: [
                  {
                    ID: '19.1',
                    derive_seg: 'Absolute neutrophil count \u2265 1000/mm 3',
                  },
                ],
                child: [],
              },
              {
                ID: '20',
                actual_text: '\uf02d Platelets \u2265 100,000/mm 3 ',
                level: '2',
                derive_seg: [
                  {
                    ID: '20.1',
                    derive_seg: 'Platelets \u2265 100,000/mm 3',
                  },
                ],
                child: [],
              },
              {
                ID: '21',
                actual_text:
                  '\uf02d Total bilirubin \u2264 1.5 times the upper limit of normal (ULN) ',
                level: '2',
                derive_seg: [
                  {
                    ID: '21.1',
                    derive_seg:
                      'Total bilirubin \u2264 1.5 times the upper limit of normal (ULN)',
                  },
                ],
                child: [],
              },
              {
                ID: '22',
                actual_text:
                  '\uf02d Aspartate aminotransferase and alanine aminotransferase \u2264 2.5 x ULN (\u2264 5 x ULN for subjects with known liver metastasis) ',
                level: '2',
                derive_seg: [
                  {
                    ID: '22.1',
                    derive_seg:
                      'Aspartate aminotransferase and alanine aminotransferase \u2264 2.5 x ULN (\u2264 5 x ULN for subjects with known liver metastasis)',
                  },
                ],
                child: [],
              },
              {
                ID: '23',
                actual_text:
                  '\uf02d Creatinine clearance \u2265 45 mL/min (calculated by the Cockcroft-Gault formula [see Section 15.0, Appendix 5]). ',
                level: '2',
                derive_seg: [
                  {
                    ID: '23.1',
                    derive_seg:
                      'Creatinine clearance \u2265 45 mL/min (calculated by the Cockcroft-Gault formula [see Section 15.0, Appendix 5]).',
                  },
                ],
                child: [],
              },
            ],
          },
          {
            ID: '24',
            actual_text:
              '11. Female subjects are eligible to enter and participate in the study if they are of: <TabTab>a Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who<TabTabTab>\u2022 Has had a hysterectomy, <TabTabTab>\u2022 Has had a bilateral oophorectomy (ovariectomy), <TabTabTab>\u2022 Has had a bilateral tubal ligation, or <TabTabTab>\u2022 Is post-menopausal (total cessation of menses for \u2265 1 year). <TabTab>b Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), and uses adequate contraception before study entry and throughout the study until 28 days after the last investigational product administration. Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:<TabTabTab>\u2022 Vasectomized partner who is sterile prior to the female subject\u2019s entry and is the sole sexual partner for that female. <TabTabTab>\u2022 Any intrauterine device with a documented failure rate of less than 1% per year. <TabTabTab>\u2022 Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.',
            level: '1',
            derive_seg: [
              {
                ID: '24.1',
                derive_seg:
                  'Female subjects are eligible to enter and participate in the study if they are of',
              },
            ],
            child: [
              {
                ID: '25',
                actual_text:
                  'a Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who<TabTabTab>\u2022 Has had a hysterectomy, <TabTabTab>\u2022 Has had a bilateral oophorectomy (ovariectomy), <TabTabTab>\u2022 Has had a bilateral tubal ligation, or <TabTabTab>\u2022 Is post-menopausal (total cessation of menses for \u2265 1 year). ',
                level: '2',
                derive_seg: [
                  {
                    ID: '25.1',
                    derive_seg:
                      'Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who',
                  },
                ],
                child: [
                  {
                    ID: '26',
                    actual_text: '\u2022 Has had a hysterectomy, ',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '26.1',
                        derive_seg: 'Has had a hysterectomy,',
                      },
                    ],
                    child: [],
                  },
                  {
                    ID: '27',
                    actual_text:
                      '\u2022 Has had a bilateral oophorectomy (ovariectomy), ',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '27.1',
                        derive_seg:
                          'Has had a bilateral oophorectomy (ovariectomy),',
                      },
                    ],
                    child: [],
                  },
                  {
                    ID: '28',
                    actual_text:
                      '\u2022 Has had a bilateral tubal ligation, or ',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '28.1',
                        derive_seg: 'Has had a bilateral tubal ligation, or',
                      },
                    ],
                    child: [],
                  },
                  {
                    ID: '29',
                    actual_text:
                      '\u2022 Is post-menopausal (total cessation of menses for \u2265 1 year). ',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '29.1',
                        derive_seg:
                          'Is post-menopausal (total cessation of menses for \u2265 1 year).',
                      },
                    ],
                    child: [],
                  },
                ],
              },
              {
                ID: '30',
                actual_text:
                  'b Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), and uses adequate contraception before study entry and throughout the study until 28 days after the last investigational product administration. Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:<TabTabTab>\u2022 Vasectomized partner who is sterile prior to the female subject\u2019s entry and is the sole sexual partner for that female. <TabTabTab>\u2022 Any intrauterine device with a documented failure rate of less than 1% per year. <TabTabTab>\u2022 Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.',
                level: '2',
                derive_seg: [
                  {
                    ID: '30.1',
                    derive_seg:
                      'Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), and uses adequate contraception before study entry and throughout the study until 28 days after the last investigational product administration.',
                  },
                  {
                    ID: '30.2',
                    derive_seg:
                      'Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:',
                  },
                ],
                child: [
                  {
                    ID: '31',
                    actual_text:
                      '\u2022 Vasectomized partner who is sterile prior to the female subject\u2019s entry and is the sole sexual partner for that female. ',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '31.1',
                        derive_seg:
                          'Vasectomized partner who is sterile prior to the female subject\u2019s entry and is the sole sexual partner for that female.',
                      },
                    ],
                    child: [],
                  },
                  {
                    ID: '32',
                    actual_text:
                      '\u2022 Any intrauterine device with a documented failure rate of less than 1% per year. ',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '32.1',
                        derive_seg:
                          'Any intrauterine device with a documented failure rate of less than 1% per year.',
                      },
                    ],
                    child: [],
                  },
                  {
                    ID: '33',
                    actual_text:
                      '\u2022 Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.',
                    level: '3',
                    derive_seg: [
                      {
                        ID: '33.1',
                        derive_seg:
                          'Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.',
                      },
                    ],
                    child: [],
                  },
                ],
              },
            ],
          },
        ],
      },
    ],
  },
];
export default data;
